At the August 2026 Practical Updates in Primary Care Virtual Meeting, Rakesh Jain, MD, MPH, and Laura Melaro, DNP, APRN, FNP-BC, PMHNP-BC, outlined a practical primary care approach to adult...
A randomized crossover trial examined whether N-of-1 deprescribing trials could identify older men receiving little symptomatic benefit from chronic tamsulosin therapy.
The FDA granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab, hyaluronidase-fihj, and dexamethasone for adults with multiple myeloma previously treated with a proteasome...
In a post-hoc analysis of a phase 3, open-label, 52-week LTE trial presented at the American Headache Society 68th Annual Scientific Meeting in Orlando, FL., ubrogepant 100 mg showed consistent 2-hour pain...
Several sessions at the 2026 American Association of Nurse Practitioners National Conference in Las Vegas, NV, addressed migraine-related diagnosis, treatment, red flags, and care considerations across...
In this expert interview, W. Clay Jackson, MD, DipTh, discusses why deprescribing should be approached through shared decision-making, careful medication review, and attention to each patient’s current...
On May 1, the FDA approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for adults with estrogen receptor–positive, human epidermal growth factor receptor 2–negative, ESR1-mutated...
The FDA has approved dextromethorphan-bupropion extended-release tablets for agitation associated with Alzheimer disease dementia, offering clinicians a non-antipsychotic treatment option supported by...
The FDA has approved a supplemental indication for lumateperone to reduce relapse risk in adults with schizophrenia based on phase 3 randomized withdrawal data.
A systematic review and meta-analysis evaluated whether pharmacist-led deprescribing interventions reduce polypharmacy and potentially inappropriate medications among older adults across care settings.
...
